--- title: "Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow" type: "News" locale: "en" url: "https://longbridge.com/en/news/274082232.md" description: "Biotech company Regeneron is set to report its Q4 earnings tomorrow before the market opens. Last quarter, it exceeded revenue expectations by 5.1%, with revenues of $3.75 billion. Analysts predict this quarter's revenue will remain flat at $3.78 billion, with adjusted earnings expected at $10.64 per share. Regeneron has missed revenue estimates twice in the past two years. Currently, the stock is down 3.1% over the last month, with an average analyst price target of $831.38 against a current price of $753.64." datetime: "2026-01-29T03:03:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274082232.md) - [en](https://longbridge.com/en/news/274082232.md) - [zh-HK](https://longbridge.com/zh-HK/news/274082232.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274082232.md) | [繁體中文](https://longbridge.com/zh-HK/news/274082232.md) # Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow Biotech company Regeneron will be reporting earnings this Friday before market open. Here’s what investors should know. Regeneron beat analysts’ revenue expectations by 5.1% last quarter, reporting revenues of $3.75 billion, flat year on year. It was an incredible quarter for the company, with an impressive beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates. Is Regeneron a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, analysts are expecting Regeneron’s revenue to be flat year on year at $3.78 billion, slowing from the 10.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $10.64 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Regeneron has missed Wall Street’s revenue estimates twice over the last two years. With Regeneron being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Regeneron is down 3.1% during the same time and is heading into earnings with an average analyst price target of $831.38 (compared to the current share price of $753.64). ### Related Stocks - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [Regeneron Pharmaceuticals, Inc. (REGN.US)](https://longbridge.com/en/quote/REGN.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [Regeneron Gets FDA OK for Extended Eylea HD Dosing](https://longbridge.com/en/news/281556416.md) - [Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients](https://longbridge.com/en/news/278381000.md) - [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/en/news/281025352.md) - [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/en/news/281051985.md) - [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/en/news/281024362.md)